David Reboussin to Antihypertensive Agents
This is a "connection" page, showing publications David Reboussin has written about Antihypertensive Agents.
Connection Strength
4.180
-
Reboussin DM, Whelton PK. Joint modeling of systolic blood pressure and the primary outcome in Systolic Blood Pressure Intervention Trial. J Hypertens. 2019 08; 37(8):1729.
Score: 0.540
-
Reboussin DM, Carey RM, Whelton PK. Evidence Supporting the Blood Pressure Treatment Goal of Less Than 130/80 mm?Hg. Hypertension. 2019 05; 73(5):972-974.
Score: 0.530
-
Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR, Polonsky T, Thompson-Paul AM, Vupputuri S. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018 10 23; 138(17):e595-e616.
Score: 0.511
-
Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR, Polonsky T, Thompson-Paul AM, Vupputuri S. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 06; 71(6):e116-e135.
Score: 0.479
-
Wright JT, Whelton PK, Reboussin DM. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2016 06 09; 374(23):2294.
Score: 0.434
-
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2021 05 20; 384(20):1921-1930.
Score: 0.153
-
Rapp SR, Gaussoin SA, Sachs BC, Chelune G, Supiano MA, Lerner AJ, Wadley VG, Wilson VM, Fine LJ, Whittle JC, Auchus AP, Beddhu S, Berlowitz DR, Bress AP, Johnson KC, Krousel-Wood M, Martindale-Adams J, Miller EC, Rifkin DE, Snyder JK, Tamariz L, Wolfgram DF, Cleveland ML, Yang M, Nichols LO, Bryan RN, Reboussin DM, Williamson JD, Pajewski NM. Effects of intensive versus standard blood pressure control on domain-specific cognitive function: a substudy of the SPRINT randomised controlled trial. Lancet Neurol. 2020 11; 19(11):899-907.
Score: 0.147
-
Nasrallah IM, Pajewski NM, Auchus AP, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, Davatzikos C, Desiderio L, Doshi J, Erus G, Fine LJ, Gaussoin SA, Harris D, Johnson KC, Kimmel PL, Kurella Tamura M, Launer LJ, Lerner AJ, Lewis CE, Martindale-Adams J, Moy CS, Nichols LO, Oparil S, Ogrocki PK, Rahman M, Rapp SR, Reboussin DM, Rocco MV, Sachs BC, Sink KM, Still CH, Supiano MA, Snyder JK, Wadley VG, Walker J, Weiner DE, Whelton PK, Wilson VM, Woolard N, Wright JT, Wright CB, Williamson JD, Bryan RN. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA. 2019 08 13; 322(6):524-534.
Score: 0.135
-
Reboussin DM, Pajewski NM, Williamson JD. Analysis of Long-term Benefits of Intensive Blood Pressure Control-Reply. JAMA. 2019 07 09; 322(2):170.
Score: 0.134
-
Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, Davatzikos C, Desiderio L, Erus G, Fine LJ, Gaussoin SA, Harris D, Hsieh MK, Johnson KC, Kimmel PL, Tamura MK, Launer LJ, Lerner AJ, Lewis CE, Martindale-Adams J, Moy CS, Nasrallah IM, Nichols LO, Oparil S, Ogrocki PK, Rahman M, Rapp SR, Reboussin DM, Rocco MV, Sachs BC, Sink KM, Still CH, Supiano MA, Snyder JK, Wadley VG, Walker J, Weiner DE, Whelton PK, Wilson VM, Woolard N, Wright JT, Wright CB. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019 02 12; 321(6):553-561.
Score: 0.131
-
Johnson KC, Whelton PK, Cushman WC, Cutler JA, Evans GW, Snyder JK, Ambrosius WT, Beddhu S, Cheung AK, Fine LJ, Lewis CE, Rahman M, Reboussin DM, Rocco MV, Oparil S, Wright JT. Blood Pressure Measurement in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2018 05; 71(5):848-857.
Score: 0.123
-
Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, Umanath K, Rahbari-Oskoui F, Porter AC, Pisoni R, Lewis CE, Lewis JB, Lash JP, Katz LA, Hawfield AT, Haley WE, Freedman BI, Dwyer JP, Drawz PE, Dobre M, Cheung AK, Campbell RC, Bhatt U, Beddhu S, Kimmel PL, Reboussin DM, Chertow GM. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis. 2018 03; 71(3):352-361.
Score: 0.120
-
Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, Miller EPR, Polonsky T, Thompson-Paul AM, Vupputuri S. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 05 15; 71(19):2176-2198.
Score: 0.120
-
Chang TI, Reboussin DM, Chertow GM, Cheung AK, Cushman WC, Kostis WJ, Parati G, Raj D, Riessen E, Shapiro B, Stergiou GS, Townsend RR, Tsioufis K, Whelton PK, Whittle J, Wright JT, Papademetriou V. Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension. 2017 10; 70(4):751-758.
Score: 0.117
-
Whelton PK, Reboussin DM, Fine LJ. Comparing the SPRINT and the HOPE-3 Blood Pressure Trial. JAMA Cardiol. 2016 11 01; 1(8):855-856.
Score: 0.112
-
Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015 Nov 26; 373(22):2103-16.
Score: 0.104
-
Cushman WC, Whelton PK, Fine LJ, Wright JT, Reboussin DM, Johnson KC, Oparil S. SPRINT Trial Results: Latest News in Hypertension Management. Hypertension. 2016 Feb; 67(2):263-5.
Score: 0.104
-
Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT, Whelton PK. The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials. 2014 Oct; 11(5):532-46.
Score: 0.094
-
Chang TI, Reboussin DM, Chertow GM, Cheung AK, Cushman WC, Kostis WJ, Parati G, Riessen E, Shapiro B, Stergiou GS, Tsioufis K, Whelton PK, Whittle J, Wright JT, Papademetriou V. Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions? J Clin Hypertens (Greenwich). 2018 11; 20(11):1644-1645.
Score: 0.032
-
Cheung AK, Chertow GM, Greene T, Kimmel PL, Rahman M, Reboussin D, Rocco M. Benefits and risks of intensive blood-pressure lowering in advanced chronic kidney disease. J Intern Med. 2018 07; 284(1):106-107.
Score: 0.031
-
Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J. Effects of Intensive BP Control in CKD. J Am Soc Nephrol. 2017 Sep; 28(9):2812-2823.
Score: 0.029